More information released on CEMIPP consultation

The cost-effectiveness methodology for immunisation programmes and procurement (CEMIPP) is currently under review, following a report in 2016. A consultation is underway but has required more details in order to achieve good quality input.

This latest report explains that this cost-effectiveness review is part of a drive to ensure budgets are allocated in the most efficient way, giving the greatest benefit. In the 2016 report, changes were recommended around aspects of pricing such as the cost-effectiveness threshold, discount rate and time horizons.

The report has also summarised some of the expected changes in the cost-effective prices for certain vaccines under different combinations of the 2016 report’s recommendations. For example, if the £15k/QALY threshold is adopted, the cost-effective price of the HPV vaccine will be decreased. However, if the £15k/QALY threshold and and unlimited timescale are adopted, the cost-effective price of the HPV vaccine will rise significantly. The case studies in the information linked below give a good sense of the implications of the report, and good insights into how to respond to the consultation.

Please click here to take part in the consultation.

Please click here to read the latest report and further information in full.

Please click here to read the original 2016 report.

Tagged with

Published 18. May 2018 in News UK